Glenmark Pharmaceuticals Ltd (GLENMARK) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Glenmark Pharmaceuticals reported a consolidated revenue of INR 33,876 million in Q3 FY25, a 35.1% YoY growth.
- India formulations business saw a significant 300% YoY growth, contributing 31.4% to the overall revenue.
- North America business experienced a modest 1.4% YoY growth, facing challenges due to a lack of major launches.
- Europe operations achieved a 14.8% YoY growth, driven by the branded business and key brands like RYALTRIS.
- ROW region witnessed a 3% YoY growth, impacted by adverse currency movements in key markets.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.